Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: "Since 1973, the World Symposia on Pulmonary Hypertension has contributed to the ongoing scientific advancement of our field. We are delighted to present seven thematic posters on the world stage showcasing YUTREPIA and L606. We look forw ...

Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present seven posters related to its product pipeline at the 7th World Symposia of Pulmonary Hypertension (WSPH) taking place June 29 to July 1, 2024, in Barcelona, Spain. The ...

MORRISVILLE, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that on May 31, Judge Andrews of the U.S. District Court for the District of Delaware (District Court) denied the motion for preliminary injunction filed by United Therapeutics (UTHR) that sought to block the launch of Liquidia's YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The ruling reinforces the clear path for the U.S. F ...

Liquidia Technologies, Inc. (LQDA) has been beaten down lately with too much selling pressure. While the stock has lost 11.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum ...

Exhibit 99.1 Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update MORRISVILLE, N.C., May 13, 2024 – Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia's chief executive officer, said: "We continue to vigorously pursue final agency action for YUTREPIA's ...

MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a corporate update. Court denied United Therapeutics' Request for Injunctive Relief in Lawsuit Against FDA. UTHR filed a separate lawsuit against FDA in the U.S. District Court for the District of Columbia (Case No. 1:24-cv00484- JDB), and ...

or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission File Number: 001-39724 LIQUIDIA CORPORATION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2024 (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | | - ...

MORRISVILLE, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today the company will present data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in people with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, California. Rajeev Saggar, MD, chief medical ...

Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Conference Call March 13, 2024 8:30 AM ET Company Participants Roger Jeffs - CEO Scott Moomaw - CCO Michael Kaseta - COO & CFO Rajeev Saggar - CMO Jason Adair - CBO Rusty Schundler - General Counsel Conference Call Participants Mary Kate Davis - Bank of America Julian Harrison - BTIG Serge Belanger - Needham & Company Matt Kaplan - Ladenburg Thalmann Kambiz Yazdi - Jefferies Operator Good morning, and welcome everyone to the Liquidia Corporation Full-Year ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | | --- | --- | | ( ...